ELANIX BIOTECHNOLOGIES AG Securing Funding, Adding Staff and Moving to Larger Offices
Nyon, Switzerland and Potsdam, Germany, September 1, 2016 — Elanix Biotechnologies AG (FSE: ELN), a developer of tissue regeneration products, announced today to enter in the next more operative intensive stage. In the past months the folowing key events took place:
1) June 20, 2016 Tomas Svoboda becomes sole Chief Executive Officer (CEO) of Elanix Biotechnologies AG after being CEO of the private Swiss based Elanix entities since their inception in 2013.
Mr. Svoboda joins Elanix with +30 years in life science industry, working in medical devices, in-vitro diagnostics, drug delivery, contract engineering and e-health in 6 different countries. Following, over 16 years working in international life science corporations (Serono, Haemonetics, Boston Scientific), Mr. Svoboda moved in year 2000 into an entrepreneurial environment where he co-founded and/or managed 5 medical device start-ups but also participated in executive-in-residence assignments for several medical corporations.
2) June -August 2016 – Elanix completed 2 capital increases totaling EUR 1,5 Mio at large through placing assigned number of shares to 3 qualified investors. The secured funds allow to enlarge the team and scale up sales activities as well territorial expansion of cell-tech OTC ointments.
3) August 29 2016 – Elanix completed hiring of four additional life science professionals for its Swiss Headquarters in Nyon. The team that will move in new offices before end of September will be pursuing the execution of agreed business plan and commercial activities through 3 distinct business units – OTC (Over the Counter), TEP (Tissue Engineering Products) and CaaS (Cells as a Service).
“Elanix is entering an exciting new stage of corporate development and growth following the reverse merger onto the Frankfurt Stock Exchange from last December. Our key focus will be in helping to grow the company by executing its business plan around 3 product categories. We plan to establishing cooperation and partnership agreements with third parties around the world to meet our ambitious sales, distribution and development objectives with our cell technology platform in order to treat or save ever more patients.” stated Mr. Svoboda.
Elanix Biotechnologies (Frankfurt: ELN.F) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2013 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks with vast quantities of cells of different cell types.
The Company is headquartered in Nyon, Switzerland with offices in Potsdam and listed on the Frankfurt stock exchange under the symbol ELN. For more information and updates, visit www.elanix-biotechnologies.com.
Elanix Biotechnologies AG
Disclaimer / Forward-looking statements:
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Elanix Biotechnologies AG. This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the “United States”), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.